W. Harel

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

M S Mitchell, June Kan‐Mitchell, Raymond A. Kempf et al. · PubMed · 1988 · 237 citations

Medicine, Immunology, Oncology +16

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

M S Mitchell, Raymond A. Kempf, W. Harel et al. · Journal of Clinical Oncology · 1988 · 197 citations

Medicine, Oncology, Pharmacology +17

Active-specific immunotherapy for melanoma.

M S Mitchell, W. Harel, Raymond A. Kempf et al. · Journal of Clinical Oncology · 1990 · 184 citations

Medicine, Immunology, Oncology +16

Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Actiona

Malcolm S. Mitchell, W. Harel, June Kan‐Mitchell et al. · Annals of the New York Academy of Sciences · 1993 · 97 citations

Medicine, Immunology, Oncology +17

Association of HLA phenotype with response to active specific immunotherapy of melanoma.

M S Mitchell, W. Harel, Susan Groshen · Journal of Clinical Oncology · 1992 · 81 citations

Life Sciences, Immunology, Oncology +17